The US Food and Drug Administration (FDA) has granted tentative approval for Viatris’ new drug application of a single-tablet regimen to treat HIV-1 infection in the paediatric population.

The once-a-day tablet for oral suspension comprises a fixed-dose combination of 60mg abacavir, 5mg dolutegravir and 30mg lamivudine.

Viatris noted that the therapy is indicated for use in children weighing a minimum of 6kg to less than 25kg and has a strawberry flavour.

The recommended dose of the treatment is weight proportionate and is not intended for usage in patients with a previous hypersensitivity reaction to abacavir as well as in individuals who are HLAB*5701-positive. 

This tentative approval will aid in making submissions to regulatory authorities, manufacturing and supply of the new paediatric formulation in 123 low and middle-income countries.

Viatris has a licensing agreement in place with the Medicines Patent Pool for paediatric dolutegravir.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

To manufacture and supply HIV treatment, the company signed a development deal with ViiV Healthcare and the Clinton Health Access Initiative.

The combination treatment is currently recommended by the World Health Organization as a first-line treatment for paediatric HIV patients. 

Viatris Emerging Asia and Access Markets India president Rakesh Bamzai said: “Over the years, we have continued to seek improvements to existing molecules to better meet patient needs – we have introduced novel heat-stable generic formulations, more convenient packaging options and paediatric therapies.

“The approval of this single-tablet regimen – the fixed-dose combination of abacavir 60mg/dolutegravir 5mg/lamivudine 30mg – will reduce the pill burden for children living with HIV.”